Clinical Trial Update: A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038) [Phase 1]

View source ↗

Summary

Phase 1 radiolabeled mass balance study of [14C]-ertugliflozin (MK-8835) in healthy male participants has completed. The trial examined pharmacokinetics and mas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Ertugliflozin (ertugliflozin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Status: COMPLETED